Cancer stem cells have been proposed to be responsible for tumorigenesis and recurrence in various neoplastic diseases, including multiple myeloma (MM). We have previously reported that MM cells specifically express HLA class I at high levels and that singlechain Fv diabody against this molecule markedly induces MM cell death. Here we investigated the effect of a new diabody (C3B3) on cancer stem cell-like side population (SP) cells. SP fraction of MM cells highly expressed ABCG2 and exhibited resistance to chemotherapeutic agents; however, C3B3 induced cytotoxicity in both SP cells and main population (MP) cells to a similar extent. Moreover, C3B3 suppressed colony formation and tumorigenesis of SP cells in vitro and in vivo. Crosslinking of HLA class I by C3B3 mediated disruption of lipid rafts and actin aggregation, which led to inhibition of gene expression of b-catenin and pluripotencyassociated transcription factors such as Sox2, Oct3/4 and Nanog. Conversely, knockdown of Sox2 and Oct3/4 mRNA reduced the proportion of SP cells, suggesting that these factors are essential in maintenance of SP fraction in MM cells. Thus, our findings reveal that immunotherapeutic approach by engineered antibodies can overcome drug resistance, and provide a new basis for development of cancer stem cell-targeted therapy.
INTRODUCTION
Multiple myeloma (MM) remains an incurable disease despite recent advances in high-dose chemotherapy and novel agents including thalidomide, lenalidomide and bortezomib. 1 Although the outcome of MM patients has been improved in recent years, 2 most patients eventually relapse even in achievement of complete remission. Like other types of tumors, the existence of myeloma cancer stem cells is proposed, 3, 4 and such cells are considered to contribute to disease relapse through its drug-resistant nature. Therefore, novel therapeutic modalities that target cancer stem cells are needed to further improve the prognosis of MM.
Over the past decades, human MM cancer stem cells have been studied extensively. Hamburger and Salmon 5 have reported that 486% of tumor samples from MM patients were capable of colony formation at a frequency of 1 in 1000 to 100 000 cells. Because of their extreme rarity, alternative approaches have also been developed. Side population (SP) cells are identified by their ability to efflux Hoechst 33342 dye, and these cells have been shown to highly express ABCG2 transporter that is responsible for drug resistance. [6] [7] [8] [9] In MM, the distinct fraction of SP cells has been detected in both MM cell lines and primary MM cells. 10 Matsui et al. 11 have found the clonogenic property and drug resistance in SP fraction of MM cells, and reported the relationship between SP fraction and CD138 À phenotype. Recently, Jakubikova et al. 12 have shown the clonogenic potential of SP cells, although they observed the heterogeneity in CD138 expression of SP cells. Thus, SP cells can be used as a surrogate fraction of MM cancer stem cells for developing novel strategies to overcome drug resistance. In recent years, cellular signaling pathways that control selfrenewal and differentiation have been investigated in various stem cells and cancer stem cells. 13 Several studies have shown that Wingless-related protein (Wnt) 14 and Hedgehog 15 signal pathways have an important role in self-renewal process of cancer stem cells. In MM, Wnt, 16 Hedgehog 17 and Notch 18 signaling has been shown as a critical pathway for the growth of MM cells. Specifically, b-catenin, a key regulator of Wnt pathway is illegitimately activated in MM cells. 16, 19 However, the role of Wnt/ b-catenin pathway for MM cancer stem cells remains unknown. On the other hand, the Oct4/Sox2/Nanog pluripotency axis has consistently been reiterated as the central pathway of pluripotency and self-renewal in embryonic stem cells. 20, 21 These pluripotency-associated transcription factors have been shown to reprogram somatic cells into induced pluripotent stem cells in both mouse and human models. 22, 23 Because b-catenin also regulates expression of these pluripotency-associated genes, Monoclonal antibody (mAb)-based therapy has emerged as an important therapeutic strategy in patients with neoplastic diseases. Immunotherapeutic approaches by humoral and cellular immunity might be a critical strategy that is not dependent on the cell cycle status and drug responsiveness of tumor cells. Cell surface HLA class I and b2-microglobulin complex have been expected as a target for antibody therapy in MM cells. 26 Previously, we have demonstrated that HLA class I molecules are overexpressed in MM cells and that a recombinant single-chain Fv diabody against this molecule efficiently crosslinks HLA class I and induces rho-mediated actin aggregation, which leads to MM cell death without effector function. 27, 28 In this study, we generated a new diabody specific to HLA class I molecule (C3B3) and investigated its potential on cancer stem cell-like fraction of MM cell lines and primary MM cells, focusing on the regulation of b-catenin and pluripotency-associated transcription factors.
MATERIALS AND METHODS

Cell lines
Human myeloma cell line RPMI 8226 was obtained from the Health Science Resources Bank (Osaka, Japan). KMS-11 and U266 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). KMS12-BM was obtained from the Health Science Resources Bank. MM.1S and INA-6 were kindly provided by Dr Steven Rosen (Northwestern University, Chicago, IL, USA) and Dr Martin Gramatzki (University of Kiel, Kiel, Germany), respectively. Primary stroma cell line was established from bone marrow cell culture of a patient with acute lymphocytic leukemia. Cells were cultured in RPMI 1640 medium supplemented with 5% fetal bovine serum.
Patient samples
The use of patient samples was approved by the Institutional Review Board at University of Tokushima (Tokushima, Japan), and informed consent was provided according to the Declaration of Helsinki. Primary MM cells were enriched from bone marrow aspiration cells by negative selection with the antibody cocktail for human MM cell enrichment (Stem Cell Technologies, Vancouver, BC, Canada). Peripheral blood stem cell (PBSC) products were obtained from myeloma patients undergoing PBSC transplantation as described previously. 29 Anti-HLA class I antibodies A mouse mAb that recognizes the a2 domain of HLA-A was prepared in our laboratory. 30 A recombinant single-chain Fv diabody (2D7) specific to the a2 domain of HLA-A was generated, as described previously. 27 A novel recombinant single-chain Fv diabody, C3B3, which could induce cell death with a higher activity than 2D7 diabody, 27 was generated as described below. HLA-A-expressing Ba/F3 cell line was used to intraperitoneally immunize MRL/lpr mice (Charles River Japan, Yokohama, Japan). The splenic lymphocytes from immunized mice were fused with mouse myeloma P3 Â 63Ag8U.1 cells (ATCC) by the conventional method. First, hybridoma culture supernatants were screened for antibodies that cause cell aggregation and cell killing against ARH-77 cells (ATCC). Next, the complimentary DNAs encoding the heavy chain variable and light chain variable regions were amplified from hybridoma cells. These complimentary DNA fragments were genetically converted to singlechiain Fv diabody format, which was designed to connect the heavy chain variable and light chain variable domains by 5-residue linker (Gly 4 Ser). ScFv genes encoding the diabodies of each clone were cloned into mammalian expression vector pCXND3. The diabodies were expressed by DG44 cell lines that were established by electroporation method. Conditioned medium of each DG44 line was harvested, and expressed diabodies were purified using affinity column chromatography, followed by size-exclusion high performance liquid chromatography on a Superdex 200HR 26/60 column (Amersham Biosciences, Tokyo, Japan). The purified samples were subjected to further evaluation of cytotoxic activity, and C3B3 had the strongest cytotoxic activity.
Reagents
The cytotoxic effect of melphalan (Sigma Chemical, St Louis, MO, USA) and bortezomib (Millennium Pharmaceuticals, Cambridge, MA, USA) was also evaluated. Cytochalasin D was obtained from Calbiochem, Cambridge, MA, USA. LiCl was obtained from Sigma Chemical.
Flow cytometry
The expression of cell surface antigens was analyzed by flow cytometry using fluorescein isothiocyanate-or phycoerythrin-labeled anti-ABCG2 (Chemicon, Temecula, CA, USA), anti-ABCB1 (Beckman Coulter, Brea, CA, USA), anti-ABCC1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-CD138 (BD Biosciences, San Jose, CA, USA) and anti-HLA-A mAb. For cell cycle analysis, cells were stained with propidium iodide and analyzed by flow cytometry using FlowJo software (Tree Star, Ashland, OR, USA). Apoptosis analysis was performed using annexin V and propidium iodide staining kit (MBL, Nagoya, Japan).
SP analysis and cell sorting
Cells (1 Â 10 6 /ml) were incubated with 5 mg/ml Hoechst 33342 (Sigma) for 90 min at 37 1C in phosphate-buffered saline containing 3% fetal bovine serum, either alone or in the presence of 100 mM verapamil (Sigma). After incubation, cells were washed and propidium iodide (1 mg/ml) was added to discriminate dead cells. SP analysis and sorting were performed using a cell sorter (Beckman Coulter).
Cell proliferation assay
Cell viability was measured by a cell proliferation assay using 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST-8, Kishida Chemical, Osaka, Japan).
Immunohistochemical staining
Cytospin specimens were stained with Wright-Giemsa and examined under a microscope. To assess the localization of HLA-A and lipid rafts, crosslinking of HLA-A was performed by incubation with Alexa 488-labeled anti-HLA-A mAb for 60 min at 37 1C, and lipid rafts were stained with Alexa 594-conjugated Cholera toxin subunit B (Invitrogen, Carlsbad, CA, USA). For immunofluorescence analysis after treatment with C3B3, cell specimens were stained with Alexa 488-labeled phalloidin (Invitrogen) or Alexa 568-labeled anti-active b-catenin (Millipore, Billerica, MA, USA). Cell nucleus were stained with 4 0 ,6-diamidino-2-phenylindole and examined by confocal microscopy. In mice models, tumor tissues were fixed in 10% buffered formalin and embedded in paraffin. Sections were stained with anti-Ki-67 (Novocastra Laboratories, Newcastle, UK), anti-Sox2 (R&D systems, Minneapolis, MN, USA) or anti-Oct3/4 mAbs (Santa Cruz Biotechnology). Detection was performed using a standard detection system (DAKO Japan, Tokyo, Japan).
Colony-forming assays
After treatment with chemotherapeutic agents or C3B3, MM cell lines, primary MM cells or PBSC products (1 Â 10 4 per dish) were plated into H4034 methylcellulose medium (Stem Cell Technologies) in triplicates for 14 days. MM cell colonies that consist of 440 cells were counted under an inverted microscope. 5 Hematopoietic stem cell colonies were classified and counted as granulocyte-macrophage colony-forming units or erythroid burst-forming units.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted from cells using TRIzol reagent (Invitrogen). For RT-PCR, 2 mg of total RNA was reverse transcribed with Superscript II (Invitrogen) in a 20-ml reaction solution. One-tenth of the RT-PCR product was used for subsequent PCR analysis with 23 to 35 cycles of 95 1C for 30 s, 58 1C for 30 s and 72 1C for 30 s. The primers used are shown in Supplementary Table 1. Induced pluripotent stem cells were obtained from the RIKEN BioResource Center (Tukuba, Japan), as established by the retrovirus-mediated transduction of four transcription factors (c-Myc, Oct3/4, Sox2 and Klf-4) into human fibroblasts. 23 Peripheral blood mononuclear cells from healthy donors were also used as a control.
Transfection
Small interfering RNA (siRNA) of Sox2 and Oct3/4 and scrambled siRNA were purchased from Invitrogen. siRNA (3.3 mg each) was transfected into RPMI 8226 cells by electroporation using a Nucleofector Kit scFv diabody suppresses myeloma cancer stem cells A Ikegame et al (Amaxa Biosystems, Koeln, Germany). The siRNAs used are shown in Supplementary Table 2.
Animal models
Severe combined immunodeficiency (SCID) mice were injected with 100 ml anti-asialo GM1 antiserum (Wako, Osaka, Japan) 1 day before tumor inoculation to eradicate residual natural killer cells. SP cells derived from RPMI 8226 (5 Â 10 6 cells) were treated with or without C3B3 (1 mg/ml) for 48 h. C3B3-treated SP cells were transplanted subcutaneously on the right side of the flank, whereas untreated SP cells were simultaneously transplanted on the left side of the flank of four SCID mice. Each tumor size was measured weekly and the tumor volume was calculated using the formula: ab Figure 1a ). This SP fraction was confirmed by disappearance after treatment with verapamil ( Figure 1b) . The main population (MP) with G0/G1 cell cycle was also identified and used as a control.
Characteristics of SP cells and MP cells We next enriched SP and MP cells from various MM cell lines using a cell sorter. SP cells from RPMI 8226 exhibited fine nuclear chromatin and expressed high levels of ABCG2, one of the ABC transporters associated with drug resistance (Figures 2a and b) . [7] [8] [9] Neither SP cells nor MP cells expressed ABCB1 and ABCC1 (Figure 2b) . Notably, SP fraction contained CD138 high cells and subpopulation with CD138 low , but most MP cells were CD138 high phenotype. In terms of target molecules of C3B3, SP cells expressed HLA class I at high levels as MP fraction (Figure 2b ). There was no difference in expression patterns of CD19, CD20, and CD38 between SP and MP cells (data not shown). Cell cycle analysis was performed 1 day after cell sorting, showing that SP cells were mainly in G0/G1 phases, whereas MP cells contained G2/M phases (Figure 2c ). The growth rate of SP cells was significantly lower than that of MP cells (Figure 2d ). In long-term (f ) Colony-forming assay using PBSC products harvested from patients with MM. PBSC products were incubated with bortezomib (Bor, 10 nM), 10 mM or C3B3 (100 ng/ml) for 2 h, and plated into methylcellulose medium. After culture for 14 days, colony formation of granulocyte-macrophage colony-forming units (CFU-GM) and BFU-E were examined. Data are shown as mean ± s.d. of three independent patients (**Po0.01). Figure 3c ). In co-culture with stroma cells, the frequency of SP cells decreased from 0.9 to 0.01% and it was difficult to evaluate the inhibitory effects of C3B3 on SP fraction (data not shown).
We then compared the efficacy of C3B3 and chemotherapeutic drugs in each fraction of RPMI 8226 and KMS-11 cells. SP and MP cells were isolated and cultured for 48 h in the presence of bortezomib, melphalan or C3B3. Annexin V/propidium iodide assay showed that SP cells were more resistant to melphalan and bortezomib than MP cells, whereas C3B3 induced cytotoxicity to a similar extent in both SP and MP cells (Figures 3d and e) .
Effect of C3B3 and chemotherapeutic drugs on the colony formation of SP and MP cells MM colony-forming assay showed that SP cells from RPMI 8226 and KMS-11 had a higher potential for colony formation than MP cells, indicating the existence of clonogenic cancer stem cells in SP fraction (Figure 4a ). Treatment with bortezomib and melphalan partially suppressed the colony formation of SP cells, whereas C3B3 dramatically inhibited this (Figures 4a-c) . To examine the time-dependent efficacy of these drugs, RPMI 8226 cells were treated for 2, 6 and 12 h and colony-forming assay was performed (Figure 4d ). Treatment with bortezomib and melphalan suppressed the colony formation in a time-dependent manner, but C3B3 markedly inhibited this even by 2 h incubation, indicating that the effect of C3B3 prolongs after binding to the target molecules.
When we examined patient bone marrow cells, treatment with melphalan suppressed the colony formation in both MM cells and normal erythroid burst-forming units whereas C3B3 suppressed only MM colony formation (Figure 4e ). The effect of C3B3 on normal hematopoiesis was also examined using PBSC products from MM patients. Treatment with bortezomib or melphalan significantly inhibited the formation of granulocyte-macrophage colony-forming units and/or erythroid burst-forming units, whereas C3B3 had no inhibitory effect on normal hematopoietic stem cells at the same concentration (Figure 4f ).
Effect of C3B3 on cell signaling pathways We further investigated the mechanism underlying the engagement of cell surface molecules and cell signaling pathways.
HLA class I is highly expressed on cell surface of MM cells and crosslinking of this molecule efficiently induced antigen capping phenomenon together with disruption of lipid rafts in RPMI 8226 cells ( Figure 5a ). As reported previously, 27, 28 this led to robust actin aggregation in the cytoplasm and eventually induces cell death (Figure 5b) . To clarify the signaling pathway involved in this effect, we first examined the phosphorylation pattern of signal-associated factors such as p44/42 MAPK, STAT3 and Akt in the presence of C3B3 with or without stimulation of interleukin-6 or IGF-1. However, unlike previous studies of anti-b2-microglobulin antibody, 31 C3B3 did not inhibit these signaling factors as evaluated by western blot analysis (data not shown).
We then analyzed alterations of various mRNA expressions by using quantitative RT-PCR array (Supplementary Methods). In a total of 252 genes related to stem cells, apoptosis and signaling pathway, we found the downregulation of Dkk1, Wnt11 and b-catenin genes that have a crucial role in the regulation of cancer stem cells including MM cells (Supplementary Table 3) . 16, 19, 32 When we examined the expression of b-catenin at protein levels, active b-catenin localized in the nucleus as a speckled pattern, but after treatment with C3B3 the amount of active b-catenin markedly decreased in the nucleus (Figure 5b ).
Effect of C3B3 on b-catenin and pluripotency-associated transcription factors Because Wnt/b-catenin signaling molecules are implicated in the maintenance of pluripotency-associated transcription factors, 24, 25 we further evaluated mRNA expression of Sox2, [33] [34] [35] Oct3/4, 36, 37 Nanog, 38, 39 Klf-4 and Bmi-1. 40 Notably, Nanog and b-catenin were more highly expressed in SP fraction than in MP fraction of RPMI 8226 cells (Figure 6a ). After treatment with C3B3, expression levels of Sox2, Oct3/4, Nanog and b-catenin were significantly suppressed both in SP and MP cells (Figure 6a ). This inhibition was protected by pretreatment with cytochalasin D, an inhibitor of actin aggregation, indicating that actin aggregation by C3B3 influences the gene expression profile (Figure 6b) . Similar results were obtained by using KMS11 and U266 cells (Figures 6a and b) . We also conducted the inhibition study of Wnt signal pathway, GSK3b by LiCl, and confirmed that inhibition of GSK3b restored the suppressive effect of C3B3 on the expression of Sox2, Oct3/4 and b-catenin (Figure 6c) .
Conversely, to assess the contribution of these transcription factors in survival of SP cells, Sox2-and Oct3/4-knockdowned 0 min 60 min Actin β-catenin None C3B3 Figure 5 . Effect of C3B3 on cell signaling pathways. (a) RPMI 8226 cells were incubated with Alexa 488-labeled anti-HLA-A mAb (1 mg/ml) for 30 min on ice and cultured for 60 min at 37 1C, and then cytospin specimens were prepared. Cells were further stained with Alexa 594-conjugated Cholera toxin subunit B for detection of lipid rafts. The specimens were examined by confocal microscopy. Scale bar, 2 mm.
(b) RPMI 8226 cells were incubated with C3B3 (1 mg/ml) for 24 h and cytospin specimens were stained with Alexa 488-labeled phalloidin for the detection of actin and Alexa 568-labeled anti-active b-catenin Ab. The specimens were examined by confocal microscopy. Scale bar, 10 mm.
RPMI 8226 cells were examined by flow cytometric SP analysis. The inhibitory effect of siRNAs was confirmed by RT-PCR, showing that mRNA expression of Sox2 and Oct3/4 was markedly decreased than control sample (Figure 6d ). The frequency of SP cells was significantly decreased by Sox2 and Oct3/4 knockdown, suggesting that these factors are essential in the maintenance of SP fraction in MM cells (Figure 6e ).
Effect of C3B3 on tumor development in vivo Finally, to evaluate the effect of C3B3 on tumor formation, we developed an in vivo model using SCID mice. SP cells isolated from RPMI 8226 were incubated in the presence or absence of C3B3, and subcutaneously inoculated into the each flank of SCID mice. Untreated SP cells formed progressively growing tumors after transplantation, whereas C3B3 treatment significantly inhibited tumor development as evidenced by the tumor volume (Figure 7a ). These tumor cells were then removed and further examined through flow cytometric SP analysis. The percentages of SP fraction of C3B3-treated SP cell tumors were significantly low when compared with those of untreated SP cell tumors (Figure 7b) . Furthermore, immunohistochemical analysis showed that Ki-67, a marker of proliferation potency, was less expressed in C3B3-treated tumors than in control tumors (Figure 7c ). The expression of Sox2 and Oct3/4 was also suppressed in C3B3-treated tumors when compared with control tumors (Figure 7c ). Taken together, these results indicate that C3B3 has a potential activity for preventing tumor development by inhibiting pluripotency-associated factors of cancer stem cell-like SP cells. We and other investigators have shown that bone marrow stroma cells can stimulate MM cell growth causing a vicious cycle through adhesion molecules and cytokines. 42, 43 Therefore, we addressed the role of bone marrow stroma cells for SP cells and found that the percentage of SP cells were rather decreased when co-cultured with bone marrow stroma cells. The reduction of SP fraction was also observed in the presence of interleukin-6, suggesting that interleukin-6 and other cytokines from stroma cells stimulate the differentiation of SP cells and regenerate the bulk of MP fraction. In contrast, Feng et al. 44 have shown that bone marrow stroma cells from MM patients can increase the percentage of SP cells via CXCR4 signaling pathway. This discrepancy may result from the use of different source of stroma cells in the experiments. Further studies on bone marrow stroma cells are needed to explore the role of bone marrow niches on cancer stem cells in MM patients.
The most important property of MM cancer stem cells is that these cells are resistant to chemotherapeutic agents. The relationship between ABCG2 expression and SP phenotype has been established, 7, 9 but other ABC transporters might also be involved in the SP phenotype and drug resistance. Previous studies have shown that SP cells were resistant to chemotherapeutic drugs such as 4-hydroxycyclophosphamide, dexamethasone, bortezomib and lenalidomide, whereas anti-CD20 antibody and complement successfully inhibited SP cells in MM. 11 In addition, SP cells have been shown to be resistant to thalidomide, but lenalidomide can decrease ABCG2 expression and inhibit SP cells and its clonogenic potential. 12 We also found that SP cells were resistant to melphalan and bortezomib but single-chain Fv diabody C3B3 could induce cytotoxicity in both SP cells and MP cells to a similar extent. Moreover, C3B3 suppressed colony formation of SP cells and tumorigenesis of MM cells in vitro and in vivo. Thus, chemotherapeutic drugs and even novel agents seem to have a limited effect on MM cancer stem cells because of the detoxification potential of cancer stem cells. Nevertheless, our results suggest that antibody-based agents can target cell surface molecules directly and have a potential to overcome drug resistance of cancer stem cells.
Recent studies have shown that lipid rafts have an important role for the maintenance of efficient self-renewal in stem cells. Lee et al. 45 have reported that the disruption of lipid rafts by treatment with methyl-b-cyclodextrin and caveolin-1 siRNA decreased the mRNA expression of pluripotency-associated factors such as Oct4, Sox2, FoxD3 and Rex1, and the cell cycle regulatory proteins including cyclin D1 and cyclin E in mouse embryonic stem cells. Here we demonstrated that crosslinking of HLA class I by C3B3 mediated disruption of lipid rafts and actin aggregation, which resulted in the inhibition of Wnt/b-catenin pathway and repression of Sox2, Oct3/4 and Nanog. These observations were further confirmed by using actin polymerization inhibitor, cytochalasin D and GSK3b inhibitor, LiCl, which prevented the repression of these pluripotencyassociated transcription factors. Thus, our results support the importance of lipid rafts and actin cytoskeleton for the efficient signal transduction and maintenance of cancer stem cells. However, the precise mechanism by which crosslinking of HLA modulates the gene expression profile in MM cancer stem cells remains to be elucidated.
The pluripotency-associated transcription factors Sox2 and Oct3/4 may represent another target antigen expressed by MM cancer stem cells. Brennan et al. 46 have reported that telomerase inhibition decreased the gene expression of Oct3/4, Sox2, Nanog and Bmi-1 in MM cancer stem cells. Actually, we have demonstrated that Sox2 and Oct3/4 were crucial factors for SP cells in MM by siRNA experiments. Furthermore, expression of these transcription factors was also important for the development of tumors as shown by in vivo experiments. Spisek et al. have reported that Sox2 were highly expressed in CD138 À clonogenic compartment of plasma cells and that anti-Sox2 T cells contribute to prevent disease progression in patients with monoclonal gammopathy. 47 Therefore, our results may support the concept that Sox2 is an attractive target for specific immunotherapy of MM.
In conclusion, our results indicate that single-chain Fv diabody C3B3 has a potential activity to overcome drug resistance of MM cancer stem cells. Therefore, antibody-based therapies targeting cancer stem cells may provide an important strategy to control and ultimately cure the disease.
